# Modulation of Nociceptive Ion Channels by Protease-Activated Receptor-2 in Inflammatory Pain: Molecular Mechanisms and Therapeutic Potential

**Authors:** Haneen Aburamadan, Yosra Lozon, Asha Caroline Cyril, Anagha Nelliyulla Parambath, Najma Mohamed Ali, Reem Kais Jan, Robin Plevin, Rajan Radhakrishnan

PMC · DOI: 10.3390/ijms27041769 · International Journal of Molecular Sciences · 2026-02-12

## TL;DR

This review explores how a receptor called PAR2 interacts with pain-related ion channels during inflammation, potentially offering new ways to treat pain.

## Contribution

The paper provides a comprehensive overview of the molecular mechanisms linking PAR2 and nociceptive ion channels in inflammatory pain.

## Key findings

- PAR2 modulates several ion channels like TRPV1, TRPV4, and ASIC3, increasing pain sensitivity during inflammation.
- The interaction between PAR2 and ion channels contributes to neuronal hyperexcitability in inflammatory conditions.
- Targeting PAR2-ion channel interactions may lead to novel therapeutic strategies for inflammatory pain.

## Abstract

Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor (GPCR) expressed in both the peripheral and central nervous systems. It plays a pivotal role in mediating neuroimmune interactions, particularly in the context of inflammation and pain. Upon activation by proteases, PAR2 modulates nociception through signaling cascades that influence key ion channels, including transient receptor potential (TRP) ion channels vanilloid 1 and 4 (TRPV1 and TRPV4), ankyrin 1 (TRPA1), acid-sensing ion channel 3 (ASIC3), P2X purinoceptor 3 (P2X3), Cav3.2 (T-type Ca2+ channel), and potassium Kv7 (M-current) channels, altering their expression and function. Through this crosstalk, PAR2 contributes to heightened neuronal excitability and pain hypersensitivity in various inflammatory conditions. In this narrative review, we highlight and discuss the mechanistic and functional interplay between PAR2 and nociceptive ion channels, which might be contributing to the pathogenesis of inflammatory pain. Targeting these specific molecular interactions between PAR2 and nociceptive ion channels may offer a promising therapeutic strategy for treating inflammatory pain.

## Linked entities

- **Proteins:** F2RL1 (F2R like trypsin receptor 1), TRPV1 (transient receptor potential cation channel subfamily V member 1), TRPV4 (transient receptor potential cation channel subfamily V member 4), TRPA1 (transient receptor potential cation channel subfamily A member 1), ASIC3 (acid sensing ion channel subunit 3), P2RX3 (purinergic receptor P2X 3), CACNA1H (calcium voltage-gated channel subunit alpha1 H)

## Full-text entities

- **Genes:** Rho (rhodopsin) [NCBI Gene 212541] {aka Noerg1, Opn2, Ops, RP4}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150] {aka GPR11, PAR2}, GNAQ (G protein subunit alpha q) [NCBI Gene 2776] {aka CMAL, G-ALPHA-q, GAQ, SWS}, LPAR2 (lysophosphatidic acid receptor 2) [NCBI Gene 9170] {aka EDG-4, EDG4, LPA-2, LPA2}, KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}, Par2 (pulmonary adenoma resistance 2) [NCBI Gene 109447], ANK1 (ankyrin 1) [NCBI Gene 286] {aka ANK, SPH1, SPH2, ankyrin-1}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, Ncoa1 (nuclear receptor coactivator 1) [NCBI Gene 17977] {aka KAT13A, NCoA-1, NRC-1, SRC-1, SRC-a, SRC1}, TRPA1 (transient receptor potential cation channel subfamily A member 1) [NCBI Gene 8989] {aka ANKTM1, FEPS, FEPS1, p120}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, VN1R17P (vomeronasal 1 receptor 17 pseudogene) [NCBI Gene 441931] {aka GPCR}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, F2rl1 (F2R like trypsin receptor 1) [NCBI Gene 116677] {aka Par-2, Par2}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Asic4 (acid-sensing ion channel family member 4) [NCBI Gene 241118] {aka Accn4, BNAC4}, Lox (lysyl oxidase) [NCBI Gene 16948] {aka TSC-160, rrg}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, Asic1 (acid-sensing ion channel 1) [NCBI Gene 11419] {aka ASIC, ASIC1a, ASIC1b, Accn2, B530003N02Rik, BNaC2}, Pla2g1b (phospholipase A2, group IB, pancreas) [NCBI Gene 18778] {aka Pla2a, sPLA2IB}, Elane (elastase, neutrophil expressed) [NCBI Gene 50701] {aka Ela2, F430011M15Rik, NE}, P2RX3 (purinergic receptor P2X 3) [NCBI Gene 5024] {aka P2X3}, Trpa1 (transient receptor potential cation channel, subfamily A, member 1) [NCBI Gene 277328] {aka Anktm1, TRPA1b}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Trpv4 (transient receptor potential cation channel, subfamily V, member 4) [NCBI Gene 63873] {aka 0610033B08Rik, OTRPC4, Trp12, VR-OAC, VRL-2, VROAC}, Tac1 (tachykinin 1) [NCBI Gene 21333] {aka 4930528L02Rik, NK-1, NK1, Nkna, PPT-A, PPTA}, Cacna1h (calcium channel, voltage-dependent, T type, alpha 1H subunit) [NCBI Gene 58226] {aka Cav3.2, MNCb-1209, alpha13.2}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Prkce (protein kinase C, epsilon) [NCBI Gene 18754] {aka 5830406C15Rik, PKC[e], PKCepsilon, Pkce}, Tff2 (trefoil factor 2 (spasmolytic protein 1)) [NCBI Gene 21785] {aka SP, mSP}, Glul (glutamate-ammonia ligase) [NCBI Gene 14645] {aka GS, Glns}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Prkd1 (protein kinase D1) [NCBI Gene 18760] {aka PKD, PKD1, Pkcm, Prkcm, nPKC-D1, nPKC-mu}, CASP6 (caspase 6) [NCBI Gene 839] {aka CSP-6, MCH2, caspase-6}, Hspg2 (perlecan (heparan sulfate proteoglycan 2)) [NCBI Gene 15530] {aka HSPG, Pcn, Plc, per}, SUCLG1 (succinate-CoA ligase GDP/ADP-forming subunit alpha) [NCBI Gene 8802] {aka GALPHA, MTDPS9, SUCLA1}, Ctss (cathepsin S) [NCBI Gene 13040] {aka Cats}, Calca (calcitonin/calcitonin-related polypeptide, alpha) [NCBI Gene 12310] {aka CA, CGRP-1, CGRP1, Calc, Calc1, Cgrp}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, Fos (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 314322] {aka c-fos}, CTSS (cathepsin S) [NCBI Gene 1520], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, Trpv1 (transient receptor potential cation channel, subfamily V, member 1) [NCBI Gene 193034] {aka OTRPC1, TRPV1alpha, TRPV1beta, VR-1, Vr1}, Tacr1 (tachykinin receptor 1) [NCBI Gene 21336] {aka Nk1r, Spr, Tac1r}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, Fos (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 14281] {aka D12Rfj1, c-fos, cFos}, SUCLG2 (succinate-CoA ligase GDP-forming subunit beta) [NCBI Gene 8801] {aka G-SCS, GBETA, GTPSCS}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, DAG1 (dystroglycan 1) [NCBI Gene 1605] {aka 156DAG, A3a, AGRNR, DAG, LGMDR16, MDDGA9}, CACNA1H (calcium voltage-gated channel subunit alpha1 H) [NCBI Gene 8912] {aka CACNA1HB, Cav3.2, ECA6, EIG6, HALD4}, ARRB1 (arrestin beta 1) [NCBI Gene 408] {aka ARB1, ARR1}, Prkcg (protein kinase C, gamma) [NCBI Gene 24681] {aka PKC, PKCI, Prkc, Prkcc, RATPKCI}, Asic3 (acid-sensing ion channel 3) [NCBI Gene 171209] {aka Accn3, DRASIC, SLNAC1, TNAC1}, ASIC3 (acid sensing ion channel subunit 3) [NCBI Gene 9311] {aka ACCN3, DRASIC, SLNAC1, TNaC1}, TRPV4 (transient receptor potential cation channel subfamily V member 4) [NCBI Gene 59341] {aka BCYM3, CMT2C, HMSN2C, OTRPC4, SMAL, SPSMA}
- **Diseases:** arthritis (MESH:D001168), bladder epithelial carcinoma cell line (MESH:D009375), nociceptive (MESH:D059226), acidosis (MESH:D000138), diabetic neuropathy (MESH:D003929), ischemic stroke (MESH:D002544), thermal hypersensitivity (MESH:D004342), inflammatory bowel disease (MESH:D015212), chronic pain (MESH:D059350), tissue injury (MESH:D017695), allodynia (MESH:D006930), Inflammatory Pain (MESH:D010146), endometriosis (MESH:D004715), gout (MESH:D006073), nonerosive reflux disease (MESH:D005764), injury to (MESH:D014947), Inflammatory (MESH:D007249), edema (MESH:D004487), pancreatitis (MESH:D010195), visceral pain (MESH:D059265), itch (MESH:D011537), acute pain (MESH:D059787), cystitis (MESH:D003556)
- **Chemicals:** proton (MESH:D011522), potassium (MESH:D011188), H2O2 (MESH:D006861), 4alphaPDD (-), XE991 (MESH:C112297), Bafetinib (MESH:C506918), SL-NH2 (MESH:C112356), FSLLRY-NH2 (MESH:C508716), acrolein (MESH:D000171), lipid (MESH:D008055), nitro-oleic acid (MESH:C000656258), AP (MESH:D000667), ATP (MESH:D000255), capsaicin (MESH:D002211), mustard oil (MESH:C027793), calcium (MESH:D002118), allicin (MESH:C006452), diacylglycerol (MESH:D004075), GDP-beta-S (MESH:C023427), triphenyl tetrazolium chloride (MESH:C009591), AITC (MESH:C004471), P (MESH:D010758), SLIGRL (MESH:C099570), 5,6-Epoxyeicosatrienoic acid (MESH:C040776), menthol (MESH:D008610), prostaglandins (MESH:D011453), PIP2 (MESH:D019269), 1,2-Bis-(o-Aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (MESH:C025603), cinnamaldehyde (MESH:C012843), arachidonic acid (MESH:D016718), alpha,beta-meATP (MESH:C002630), PGE2 (MESH:D015232), IP3 (MESH:D015544), N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide (MESH:C475772), BAPTA-AM (MESH:C070379), cAMP (MESH:D000242), glutamate (MESH:D018698)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Armoracia rusticana (horseradish, species) [taxon 3704], Mus musculus (house mouse, species) [taxon 10090], Allium sativum (garlic, species) [taxon 4682]
- **Cell lines:** HBE — Homo sapiens (Human), Transformed cell line (CVCL_0287), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), T24 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_0554), epithelial — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_EE38), kidney — Homo sapiens (Human), Undefined cell line type (CVCL_WH75), root ganglion — Capra hircus (Goat), Finite cell line (CVCL_IR22), human — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_VN30), CHO — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_0213), HEK — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_M624)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941160/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941160/full.md

## References

107 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941160/full.md

---
Source: https://tomesphere.com/paper/PMC12941160